Senseonics Holdings Inc (SENS) Shares Sold by Telemetry Investments L.L.C.
Telemetry Investments L.L.C. cut its stake in shares of Senseonics Holdings Inc (NYSEAMERICAN:SENS) by 96.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,463 shares of the company’s stock after selling 1,441,537 shares during the quarter. Telemetry Investments L.L.C.’s holdings in Senseonics were worth $151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently made changes to their positions in the company. Great West Life Assurance Co. Can bought a new stake in shares of Senseonics in the 4th quarter worth approximately $41,000. Frontier Investment Mgmt Co. bought a new stake in shares of Senseonics in the 4th quarter worth approximately $52,000. Cerity Partners LLC lifted its holdings in shares of Senseonics by 33.3% in the 4th quarter. Cerity Partners LLC now owns 20,000 shares of the company’s stock worth $52,000 after acquiring an additional 5,000 shares during the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Senseonics in the 4th quarter worth approximately $64,000. Finally, Raymond James Trust N.A. bought a new stake in shares of Senseonics in the 3rd quarter worth approximately $210,000. Institutional investors and hedge funds own 30.66% of the company’s stock.
Shares of NYSEAMERICAN SENS traded down $0.03 during mid-day trading on Friday, hitting $2.62. The stock had a trading volume of 19,188 shares, compared to its average volume of 1,792,493. Senseonics Holdings Inc has a 1 year low of $2.15 and a 1 year high of $5.29.
SENS has been the topic of several analyst reports. Piper Jaffray Companies initiated coverage on shares of Senseonics in a research note on Tuesday, January 29th. They issued a “neutral” rating on the stock. Zacks Investment Research downgraded shares of Senseonics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. Finally, UBS Group initiated coverage on shares of Senseonics in a research note on Tuesday, November 27th. They issued a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $6.00.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More: What is Compound Interest?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.